The advisory committee said refreshed trial data from Amylyx’s ALS drug, named AMX0035, helped determine the vote. The Cambridge-based biotech company’s co-CEO, Justin Klee, also said he would withdraw the treatment from the market if a larger trial of 600 people isn’t successful.
“We will do what is right for patients,” Mr. Klee said.
ALS, also known as Lou Gehrig’s disease, is a degenerative disease that afflicts about 30,000 Americans, according to the CDC. Patients usually live one to five years after symptoms appear.
If the FDA approves AMX0035 — which could be decided by Sept. 29 — it will be the first ALS drug “that has demonstrated a significant slowing of disease progression and functional decline, as well as extended survival, in a randomized, placebo-controlled clinical trial,” Amylyx said in a Sept. 7 news release.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
